Alpha 2.0
Login Register
» Authors » Monia Ezzalfani

Monia Ezzalfani

Explore the profile of Monia Ezzalfani including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 232
Followers 0
Related Specialties
Oncology
General Medicine
Public Health
Top 10 Co-Authors
David Perol
Mathieu Robain
Cedric Hermans
Simone Mathoulin-Pelissier
Jameel Nazir
Jan Astermark
Sumithra J Mandrekar
Xavier Paoletti
Suzette Delaloge
Rui Qin
Published In
Stat Med
Ther Adv Hematol
PLoS One
J Thorac Oncol
Eur J Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: analysis of phase III trials using patient-reported outcomes
Astermark J, Hermans C, Ezzalfani M, Sidhom A, Barbier S, Kragh N, et al.
Ther Adv Hematol . 2023 Jun; 14:20406207231170701. PMID: 37283819
Background: Pain is a common symptom of hemophilia that may adversely affect patients' quality of life (QoL). Previous analyses of prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) have...
2.
Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study
Pasi J, Hermans C, Hakimi Z, Nazir J, Aballea S, Ezzalfani M, et al.
Ther Adv Hematol . 2022 Mar; 13:20406207221079482. PMID: 35237394
Background: Pain, a common symptom of hemophilia, begins early in life primarily due to joint bleeding. Recurrent bleeding adversely affects patients' pain-related physical functioning, which can negatively impact their quality...
3.
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires
Astermark J, Hermans C, Ezzalfani M, Aballea S, Santagostino E, Hakimi Z, et al.
Haemophilia . 2021 Nov; 28(1):18-26. PMID: 34761474
Introduction: Recurrent bleeding in severe haemophilia B causes painful hemarthroses and reduces capacity for physical activity. Recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis results in low annualised bleeding rates,...
4.
Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project
Ezzalfani M, Porcher R, Savignoni A, Delaloge S, Filleron T, Robain M, et al.
PLoS One . 2021 Sep; 16(9):e0255017. PMID: 34525119
Purpose: Observational studies using routinely collected data are faced with a number of potential shortcomings that can bias their results. Many methods rely on controlling for measured and unmeasured confounders....
5.
Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration
Le Tilly O, Azzopardi N, Bonneau C, Desvignes C, Oberkampf F, Ezzalfani M, et al.
Clin Pharmacol Ther . 2021 Feb; 110(1):210-219. PMID: 33547646
Intravenous administration of monoclonal antibodies leads to low concentrations in the central nervous system, which is a serious concern in neuro-oncology, especially in leptomeningeal carcinomatosis of HER2-overexpressing breast cancer. Case...
6.
Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial
Loap P, Loirat D, Berger F, Ricci F, Vincent-Salomon A, Ezzili C, et al.
Int J Radiat Oncol Biol Phys . 2020 Sep; 109(2):436-440. PMID: 32971187
Purpose: Preclinical studies have evidenced that triple-negative breast cancer (TNBC) cell lines are more sensitive to poly (ADP-ribose) polymerase inhibitors. This provides a strong rationale for developing a new therapeutic...
7.
Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma
Vairy S, Le Teuff G, Bautista F, De Carli E, Bertozzi A, Pagnier A, et al.
Neurooncol Adv . 2020 Jul; 2(1):vdaa075. PMID: 32666050
Background: New rescue regimens are needed for pediatric refractory/recurrent low-grade glioma. Nilotinib is a tyrosine kinase inhibitor that has potential synergistic effects with vinblastine on angiogenesis, tumor cell growth, and...
8.
How to design a dose-finding study on combined agents: Choice of design and development of R functions
Ezzalfani M
PLoS One . 2019 Nov; 14(11):e0224940. PMID: 31710632
Background: In oncology, the aim of dose-finding phase I studies is to find the maximum tolerated dose for further studies. The use of combinations of two or more agents is...
9.
The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME)
Perol D, Robain M, Arveux P, Mathoulin-Pelissier S, Chamorey E, Asselain B, et al.
BMJ Open . 2019 Feb; 9(2):e023568. PMID: 30796119
Purpose: The currently ongoing Epidemiological Strategy and Medical Economics (ESME) research programme aims at centralising real-life data on oncology care for epidemiological research purposes. We draw on results from the...
10.
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, et al.
Eur J Cancer . 2018 Apr; 96:17-24. PMID: 29660596
Aim: Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC) patients may help define medical needs and evaluate the impact of public health investments. The present study...